Brief: Abcellera & Rallybio To Develop Novel Antibody-Based Therapeutics For Rare Diseases
Dec 1 (Reuters) - Abcellera Biologics Inc ABCL.O :
* ABCELLERA AND RALLYBIO ANNOUNCE STRATEGIC ALLIANCE TO
DISCOVER,
DEVELOP, AND COMMERCIALIZE NOVEL ANTIBODY-BASED THERAPEUTICS FOR
RARE DISEASES
Source text for Eikon: ID:nBw70rx3Ga
Further company coverage: ABCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce